Breaking News
Get 60% Off 0
⏳ Final hours! Save up to 60% OFF InvestingPro
CLAIM SALE
Close

Marinus Pharmaceuticals Inc (61Y)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.2800 -0.0260    -8.50%
04/12 - Closed. Currency in EUR
Type:  Equity
Market:  Germany
ISIN:  US56854Q2003 
S/N:  A2QEUC
  • Volume: 450
  • Bid/Ask: 0.2800 / 0.3020
  • Day's Range: 0.2800 - 0.2880
Marinus Pharma 0.2800 -0.0260 -8.50%

Marinus Pharma Company Profile

 
Explore the Marinus Pharma company profile for core details about Marinus Pharma, assess Marinus Pharma company details, including a description of the company, key contact information, and insights into the top executives. Discover the company's operations and leadership to better understand its role in the industry.
IndustryPharmaceuticals
SectorHealthcare
Employees

166

Equity Type

ORD

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Contact Information

Address 5 Radnor Corporate Center Suite 500
100 Matsonford Road Radnor, 19087
United States
Phone 484 801 4670
Fax -

Top Executives

Name Age Since Title
Scott N. Braunstein 59 2018 CEO, President & Chairman
Seth H. Z. Fischer 68 2016 Independent Director
Christine B. Silverstein 40 2023 Independent Director
Jacqueline A. French - - Member of Scientific Advisory Board
Marvin H. Johnson 60 2023 Independent Director
Elia M. Pestana Knight - - Member of Scientific Advisory Board
Eugen Trinka - - Member of Scientific Advisory Board
Michael A. Rogawski - - Member of Scientific Advisory Board
Rajsekar R. Rajaraman - 2024 Member of the Scientific Advisory Board
Joseph E. Sullivan - 2024 Member of the Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MRNS Comments

Write your thoughts about Marinus Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email